Compare Quest Diagnostics Inc (DGX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Prologis Inc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Prologis Inc trades at $143.5 (market cap $132.85B). The key difference: Prologis Inc is far larger — about 5.8× Quest Diagnostics Inc's market cap, and Prologis Inc pays the higher dividend (3%). Which is the better fit depends on your goals.
| DGX | PLD | |
|---|---|---|
Market Cap | $22.80B | $132.85B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $148.74 |
52-Week Low | $166.42 | $104.08 |
Enterprise Value | $28.82B | $166.72B |
Dividend Yield | 1.67% | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Prologis (PLD) trades at $142.16, up 0.92% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.05 exceeding expectations of $0.806. Recent news highlights expansion into data centers and a rejected $16.9 billion bid for Segro, indicating aggressive growth ambitions. Cash flow trends show operational strength despite a net outflow in 2025, while debt-to-asset ratios have risen to 37.2%.
The outlook remains positive with a consensus price target of $155.20, offering ~9% upside. Key risks include rising leverage, execution challenges in new segments, and macroeconomic sensitivity. Institutional sentiment is bullish, but investors should monitor debt levels and integration of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
